Spotlight on JLABS
JLABS @ TMC , John P. McGovern Campus , Houston , TX 77021
January 19, 2017 from 16:00 PM to 19:00 PM (CST)
$10 - $35
Come one, come all! You are invited to learn more about some of the exciting companies creating scientific breakthroughs at JLABS in Houston. JLABS @ TMC currently holds over 20 companies and has several more in the pipeline. Four companies will give candid, informative presentations detailing their executive teams, an overview of their company and highlighting their reasons for joining JLABS. Don't miss this opportunity to learn more about the progress of this exciting project and meet the companies within JLABS. Please note that the presentations at this event will include publicly available, non-confidential information only.
Thursday, January 19, 2017
3:00 PM | Registration Opens & Overview
3:30 PM | Presentations
4:45 PM | Networking Reception
6:00 PM | Program Close
ImmunoMet Therapeutics read more»
Salarius Pharmaceuticals read more»
Seremedi read more»
Viracyte read more»
Please RSVP online so that we can get an accurate headcount for food and beverages.
JLABS @ TMC
John P. McGovern Campus
2450 Holcombe Blvd, Suite J
Houston, TX 77021
Presenting Companies' Descriptions:
As a leader in the field of cancer metabolism and immunometabolism, ImmunoMet Therapeutics continues to strive to be the forerunner in bringing the best possible innovative therapies to cancer patients. ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products that are aimed to improve the quality of life of cancer patients. With more than 6 years of experience in the field of cancer metabolism and immunometabolism, ImmunoMet has developed a comprehensive pipeline of metabolic regulators preferentially targeting the cellular metabolism of drug-resistant cancer subpopulations and immuno-suppressors of anti-cancer effector T cells. With our devotion to research and development, we aim to bring multiple metabolic regulators that can be combined with and enhance the current standard-of-care or new therapies to control cancer recurrence.
Salarius Pharmaceuticals is an emerging growth biotechnology company targeting cancer therapies for pediatric, rare, and hematologic/solid tumors. The Company's lead compound which targets LSD1 ( lysine-specific histone demethylase 1), is entering Phase 1. Salarius strategy is to explore and develop epigenetic inhibitors as novel pharmaceutical candidates cancers rely on to support their genomic program of awakening oncogenes and shutting down tumor suppressor genes. Salarius lead compound, SP-2577, is a reversible inhibitor of lysine-specific histone demethylase 1 (LSD1), an enzyme involved in abnormal epigenetic promotion of cancer. LSD1 promotes cancer by demethylating lysine 4 and lysine 9 in the histone H3. LSD1 plays a critical role in undifferentiated and translocated fusion protein sarcomas, like Ewing sarcoma, and is of particular importance for cancers like prostate and breast cancer that achieve hormonal independence. SP-2577 works by reversing the genomic program cancers leverage using LSD1 to promote growth and “stemishness.” 95% of Ewing sarcoma patient’s possess the EWS/FLI genetic translocation, the defective gene. In the Ewing’s sarcoma xenograph), SP-2577 cured all mice with Ewing’s sarcoma. In addition, SP-2577 demonstrated reversal of the genes up-regulated and down-regulated by the EWS/FLI oncoprotein in Ewing sarcoma – meaning SP-2577 demonstrated almost complete reversal of the effects of the EWS/FLI genetic translocation. The cancers initially targeted by SP-2577 are among the most devastating (Ewing sarcoma) and prevalent (prostate) in the world. If successful, SP-2577 will be first-in-class treatment option for pediatric, adolescent and adult patients of Ewing sarcoma. Proceeds from the Cancer Prevention & Research Institute of Texas (CPRIT) will be utilized to conduct pediatric, adolescent and adult Refractory Ewing’s sarcoma Phase 1 and Phase 2 clinical trials and in castration resistant prostate cancer Phase 1 and Phase 2 clinical trial program.
Seremedi, Inc., a digital health company pioneering an integrated mobile patient care platform to help healthcare providers reduce inefficiencies that lead to medical errors - the third leading cause of death in the US. Seremedi’s CareScriptions® platform introduces a ‘just-in-time’, on demand, integrated, team-based approach to the recovery process - streamlining care team efficiency and reducing cost. CareScriptions® goes beyond current telemedicine and mobile health approaches, providing real-time communication and data sharing, enabling clinicians, researchers and patients to work together as a team throughout the entire continuum of care to achieve the best possible outcome, increasing efficiencies that result in higher patient satisfaction, reduced complications and readmissions.
ViraCyte is a clinical stage company focused on treating viral infections in severely immuno-compromised patients using Tcell immunotherapy. Supported by results from multiple clinical trials and a proprietary scalable manufacturing platform, ViraCyte is positioned to develop one of the first commercial Tcell therapy products for treating severe, life threatening infections.